Pages that link to "Q60368025"
Jump to navigation
Jump to search
The following pages link to Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer (Q60368025):
Displaying 50 items.
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer (Q24632187) (← links)
- Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2 (Q24792515) (← links)
- Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy (Q26825053) (← links)
- From bench to bedside: immunotherapy for prostate cancer (Q26864390) (← links)
- Recent advances in therapeutic cancer vaccines (Q27025266) (← links)
- Identification of antigen-specific IgG in sera from patients with chronic prostatitis (Q33206641) (← links)
- Ovarian cancer immunotherapy: opportunities, progresses and challenges (Q33702218) (← links)
- The diversity of T-cell co-stimulation in the induction of antitumor immunity (Q33776121) (← links)
- Gene therapy: the first decade (Q33838263) (← links)
- Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy (Q33847896) (← links)
- Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice (Q33872776) (← links)
- Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances (Q33973408) (← links)
- Vaccines as monotherapy and in combination therapy for prostate cancer (Q34039068) (← links)
- Novel strategies and therapeutics for the treatment of prostate carcinoma (Q34043331) (← links)
- Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors (Q34169782) (← links)
- Incidence rate and management of prostate carcinoma (Q34233837) (← links)
- Immunotherapy for prostate cancer (Q34328407) (← links)
- Clinical experience with gene therapy for the treatment of prostate cancer. (Q34612517) (← links)
- Biotechnology and drug discovery--the future is here: a guide for the practicing urologist (Q34626187) (← links)
- Immunotherapy of prostate cancer (Q34707494) (← links)
- Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors (Q34787754) (← links)
- Prostate cancer as a model for tumour immunotherapy (Q34856875) (← links)
- Immunotherapy of urologic tumors: principles and progress (Q35021643) (← links)
- The potential for prostate cancer immunotherapy (Q35173081) (← links)
- Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. (Q35419821) (← links)
- Gene-based therapy in prostate cancer (Q35853023) (← links)
- Therapeutic cancer vaccines: current status and moving forward (Q35894347) (← links)
- Fighting cancer with vaccinia virus: teaching new tricks to an old dog. (Q36018992) (← links)
- Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development (Q36093425) (← links)
- PSA regulates androgen receptor expression in prostate cancer cells (Q36114365) (← links)
- Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). (Q36256563) (← links)
- Poxviral vectors for cancer immunotherapy (Q36350388) (← links)
- Technology Insight: vaccine therapy for prostate cancer (Q36395076) (← links)
- PSA-based vaccines for the treatment of prostate cancer (Q36445536) (← links)
- The anticancer immune response: indispensable for therapeutic success? (Q36677608) (← links)
- Immunotherapy in prostate cancer: emerging strategies against a formidable foe. (Q36708792) (← links)
- Advances in prostate cancer immunotherapies (Q36760292) (← links)
- Prostate cancer gene therapy clinical trials (Q36779377) (← links)
- Immunology and immunotherapy approaches for prostate cancer. (Q36786512) (← links)
- Immunotherapy for metastatic prostate cancer (Q36949548) (← links)
- Immunotherapy and immune evasion in prostate cancer (Q37061769) (← links)
- Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients (Q37068071) (← links)
- Gene-modified bone marrow cell therapy for prostate cancer (Q37127252) (← links)
- Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma (Q37210703) (← links)
- Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. (Q37455348) (← links)
- Immunotherapy for prostate cancer: an emerging treatment modality (Q37691634) (← links)
- Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer (Q37732958) (← links)
- Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy (Q37952147) (← links)
- Integrating Immunotherapies in Prostate Cancer (Q38567067) (← links)
- Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. (Q39507581) (← links)